Factor XIII-A Val34Leu polymorphism might beassociated with myocardial infarction risk: an updated meta-analysis.

Although many epidemiologic studies have investigated the FXIII-A Val34Leu polymorphism and their associations with myocardial infarction (MI), definite conclusions can't be drawn. To clarify the effects of FXIII-A Val34Leu polymorphism on the risk of MI, a meta-analysis was performed. Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) till 10 August 2014. Pooled ORs and 95% CIs were used to assess the strength of the associations. A total of 12 studies including 3139 MI cases and 6343 healthy controls were involved in this meta-analysis. A significantly decreased MI risk was found (adjusted OR = 0.70, 95% CI 0.60-0.82, P < 0.00001). In the subgroup analysis by age, significantly decreased risks were found in the young population (OR = 0.70, 95% CI 0.54-0.91, P = 0.008) and old population (OR = 0.63, 95% CI 0.50-0.80, P = 0.0001). In the subgroup analysis by gender, significantly decreased risks were found in male (OR = 0.55, 95% CI 0.34-0.88, P = 0.01) and female (OR = 0.72, 95% CI 0.55-0.95, P = 0.02). When we limited the meta-analysis to studies that controlled for confounders such as age, sex, BMI, smoking, diabetes, hypertension, dyslipidemia, and fibrinogen, a significant association between FXIII-A Val34Leu polymorphism and MI risk remained. This meta-analysis provides the evidence that FXIII-A Val34Leu polymorphism may significant associated with the MI risk.